UB Paderborn / Katalog / Suche / in CDI

1 – 13 von 13

Sortiert nach

A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first‐line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin

BJU international, 2020-08, Vol.126 (2), p.292-299

2020

Volltextzugriff (PDF)

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

BMJ open, 2023-08, Vol.13 (8), p.e069176-e069176

2023

Volltextzugriff (PDF)

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

The lancet oncology, 2020-03, Vol.21 (3), p.345-357

2020

Volltextzugriff (PDF)

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

The Lancet (British edition), 2023-01, Vol.401 (10373), p.281-293

2023

Volltextzugriff (PDF)

The biology of antihormone failure in breast cancer

Breast cancer research and treatment, 2003-01, Vol.80 Suppl 1 (S1), p.S29-34

2003

Volltextzugriff (PDF)

Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)

Endocrinology (Philadelphia), 2001-07, Vol.142 (7), p.2776-2788

2001

Volltextzugriff (PDF)

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells

Breast cancer research and treatment, 2003-09, Vol.81 (1), p.81-93

2003

Volltextzugriff (PDF)

Tracking endocrine resistance in estrogen-receptor positive breast cancer in ctDNA

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e14550-e14550

2019

Volltextzugriff (PDF)

Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial

BJC Reports, 2023-09, Vol.1 (1), Article 13

2023

Volltextzugriff (PDF)

ToTem: A phase Ib trial of temisirolimus with gemcitabine and cisplatin

Journal of clinical oncology, 2016-05, Vol.34 (15_suppl), p.e16032-e16032

2016

Volltextzugriff (PDF)

TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.448-448

2016

Volltextzugriff (PDF)

Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)1

Endocrinology (Philadelphia), 2001-07, Vol.142 (7), p.2776-2788

2001

Volltextzugriff (PDF)

The biology of antihormone failure in breast cancer. Discussion

Breast cancer research and treatment, 2003, Vol.80, p.S29-S35

2003

Volltextzugriff (PDF)

1 – 13 von 13

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(13)
Mit Volltextzugriff
(13)

Publikationsform

Artikel
(12)
Tagungsberichte
(1)

Sprache

Englisch
(13)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(6)
Life Sciences & Biomedicine
(6)
Science & Technology
(6)
Chemotherapy
(4)
Female
(4)
Aged
(3)
Breast Cancer
(3)
Breast Neoplasms - Drug Therapy
(3)
Breast Neoplasms - Pathology
(3)
Fulvestrant
(3)
Middle Aged
(3)
Oncology
(3)
Patients
(3)
Treatment Outcome
(3)
Adult
(2)
Antineoplastic Agents
(2)
Antineoplastic Agents, Hormonal - Pharmacology
(2)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(2)
Antiviral Drugs
(2)
Biological And Medical Sciences
(2)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Journal Of Clinical Oncology
(3)
Breast Cancer Research And Treatment
(2)
Endocrinology
(2)
Bjc Reports
(1)
Bju International
(1)
Bmj Open
(1)
Lancet
(1)
Lancet Oncology/lancet. Oncology
(1)
The Lancet
(1)
The Lancet Oncology
(1)

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomised Phase II trial of carboplatin and gemcitabine ± vandetanib in first‐line treatment of patients with advanced urothelial cell cancer not suitable to receive cisplatin

Platform adaptive trial of novel antivirals for early treatment of COVID-19 In the community (PANORAMIC): protocol for a randomised, controlled, open-label, adaptive platform trial of community novel antiviral treatment of COVID-19 in people at increased risk of more severe disease

Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label, platform-adaptive randomised controlled trial

The biology of antihormone failure in breast cancer

Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)

Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells

Tracking endocrine resistance in estrogen-receptor positive breast cancer in ctDNA

Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial

ToTem: A phase Ib trial of temisirolimus with gemcitabine and cisplatin

TOUCAN: A randomised phase II trial of carboplatin and gemcitabine +/- vandetanib in first line treatment of advanced urothelial cell cancer in patients who are not suitable to receive cisplatin

Enhanced Epidermal Growth Factor Receptor Signaling in MCF7 Breast Cancer Cells after Long-Term Culture in the Presence of the Pure Antiestrogen ICI 182,780 (Faslodex)1

The biology of antihormone failure in breast cancer. Discussion

Suchergebnisse filtern